|
Targetoid hemosiderotic hemangioma (hobnail hemangioma): A case report
|
Simin Shamsi Meymandi1   , Maryam Khalili2 , Mahin Aflatoonian 3 |
1- Dermatology Department, Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran.
2- Dermatology Department, Kerman University of Medical Sciences, Kerman, Iran.
3- Dermatology Department, Kerman University of Medical Sciences, Kerman, Iran. , maaflatoonian@gmail.com |
|
|
Abstract: (4785 Views) |
Background and Aim: Hobnail hemangioma ( targetoid hemosiderotic hemangioma( is a benign vascular tumor that is usually characterized as a papule with an ecchymotic halo on the periphery. It is usually seen in young adults and most commonly affects limbs. The lesion is seen equally in both sexes. This vascular tumor is rare in the world and, according to our acknowledge, only one case has been reported in Iran. In this case report, we described the second case of targetoid hemosiderotic hemangioma.
Material and Methods: The patient is an 8 years old boy with a targetoid asymptomatic red popular lesion on his lower leg from 5 years ago .The lesion was completely excised. Skin biopsy showed dilated vascular spaces with hobnail endothelial cells in the superficial dermis accompanied with narrower vessels in the deep dermis which was compatible with targetoid hemosiderotic hemangioma. In a follow up period of three years the lesion did not recur.
Conclusion: Distinction between targetoid hemosiderotic hemangioma and malignant skin lesions such as melanoma, Kaposi sarcoma and angiosarcoma is necessary. Thus, knowledge of clinical picture and pathology of this lesion can prevent unnecessary aggressive procedures.
Key words: Targetoid hemosiderotic hemangioma, Hobnail hemangioma.
Received: May 21, 2017 Accepted: Oct 16, 2017 |
|
| Keywords: Targetoid hemosiderotic hemangioma, Hobnail hemangioma. |
|
|
Full-Text [PDF 1905 kb]
(1277 Downloads)
|
Type of Study: Original Research |
Subject:
General
Received: 2018/01/24 | Accepted: 2018/01/24 | Published: 2018/01/24
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
